TBTrent E. Balius

Trent E. Balius

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Trent E. Balius has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MolSanitizer: An open-source pipeline to prepare small-molecule databases for large-scale virtual screening

    by Thua-Phong Lam, Szymon Pach, Philip Ullmann, Hocine El Khaoudi Enyoury, Ruth Brenk, Flavio Ballante, Trent E. Balius, Peter Kolb, John Irwin, Jens Carlsson, et al.

    Accurate preparation of small-molecule databases for virtual screening is crucial for the success of computer-aided drug discovery. Although numerous free software options are available, they often underperform compared to commercial alternatives. Here, we introduce MolSanitizer, an open-source molecular preparation pipeline built on RDKit and designed for large-scale virtual screening. MolSanitizer extends existing open-source functionality through curated, chemical-environment-aware rules for protonation and tautomerization, systematic stereoisomer enumeration, and a dedicated conformer generator that combines knowledge-based structural preferences with stochastic torsional sampling. Our benchmarking results show that MolSanitizer achieves better performance than several free software alternatives while achieving performance levels comparable to commercial software. MolSanitizer features a modular and open-source design, allowing users to easily customize the tool to meet their specific needs. MolSanitizer also generates output files compatible with several widely used molecular docking programs, thereby facilitating a streamlined workflow for users. MolSanitizer is available for free at https://github.com/carlssonlab/MolSanitizer and via a web server at https://carlssonlabtools.icm.uu.se/molsani.

  • Open Access

    Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS

    by Matthew J. Whitley, Marcin Dyba, Mayukh Chakrabarti, Brian P. Smith, Albert H. Chan, John-Paul Denson, Simon A. Messing, Ken Lin, Gabriel Cornilescu, Trent E. Balius, et al.

    Direct targeting of KRAS through the Switch-II pocket is an effective therapeutic strategy, but acquired resistance limits clinical benefit. We examine clinically observed resistance mutations (R68S, H95Q, Y96C, Y96D and Q99L) arising during KRAS G12C inhibitor therapy using biochemical, structural, computational and cellular approaches. Covalent and noncovalent binding measurements reveal mutation- and inhibitor-specific reductions in drug engagement across inhibitor classes. Structural analyses identify two principal resistance mechanisms: Type I, involving loss of key inhibitor contacts, and Type II, involving stabilization of pocket-occluding Switch-II conformations. Y96D exhibits both mechanisms through nucleotide-dependent non-native intramolecular interactions, whereas R68S primarily exhibits Type I resistance with modest Type II effects on pocket architecture and Switch-region dynamics. Y96C, H95Q and Q99L predominantly exhibit Type I resistance. All mutants retain RAF1 binding, whereas PI3Kα binding is selectively reduced by R68S and Q99L. Together, these findings provide structural insights for understanding on-target resistance to Switch-II pocket inhibitors.

  • Open Access

    Disulfide tethering reveals cryptic pockets in oncogenic KRAS

    by Trent E. Balius, Marcin Dyba, Vandana Kumari, John-Paul Denson, Ming Yi, Alok K. Sharma, Priyanka Prakash, Emily Alberico, Simon Messing, Vanessa Wall, et al.

    Disulfide tethering is a site-directed method of drug discovery used to identify hits for challenging targets. We applied tethering to target oncogenic KRAS, a small GTPase once considered undruggable due to its high nucleotide affinity and a perceived absence of binding sites. We prepared a library of 2160 disulfide-containing fragments. We screened over 1000 compounds against a panel of 83 engineered cysteine mutants of KRAS G12D in the active conformation and screened the full library for a subset of 30 mutants. For select mutants and hits, we performed 2-mercaptoethanol competition assays (βME-50) to prioritize ligands. Ligandability analysis comparing hit rates across mutant residues enabled the identification of druggable hot spots. Our studies confirmed known binding sites, including the Switch-II / α-helix 3 pocket. In addition, we identified previously undescribed cryptic pockets and validated select hits using computational chemistry and NMR spectroscopy. These pockets represent promising opportunities for future drug discovery campaigns.


  • Open Access

    Development of Receptor Desolvation Scoring and Covalent Sampling in DOCK 6: Methods Evaluated on a RAS Test Set

    by Y. Stanley Tan, Mayukh Chakrabarti, Reed M. Stein, Lauren E. Prentis, Robert C. Rizzo, Tom Kurtzman, Marcus Fischer, Trent E. Balius

    Molecular docking methods are widely used in drug discovery efforts. RAS proteins are important cancer drug targets, and are useful systems for evaluating docking methods, including accounting for solvation effects and covalent small molecule binding. Water often plays a key role in small molecule binding to RAS proteins, and many inhibitors-including FDA-approved drugs-covalently bind to oncogenic RAS proteins. We assembled a RAS test set, consisting of 138 RAS protein structures and 2 structures of KRAS DNA in complex with ligands. In DOCK 6, we have implemented a receptor desolvation scoring function and a covalent docking algorithm. These new features were evaluated using the test set, with pose reproduction, cross-docking, and enrichment calculations. We tested two solvation methods for generating receptor desolvation scoring grids: GIST and 3D-RISM. Using grids from GIST or 3D-RISM, water displacements are precomputed with Gaussian-weighting, and trilinear interpolation is used to speed up this scoring calculation. To test receptor desolvation scoring, we prepared GIST and 3D-RISM grids for all KRAS systems in the test set, and we compare enrichment performance with and without receptor desolvation. Accounting for receptor desolvation using GIST improves enrichment for 51% of systems and worsens enrichment for 35% of systems, while using 3D-RISM improves enrichment for 44% of systems and worsens enrichment for 30% of systems. To more rigorously test accounting for receptor desolvation using 3D-RISM, we compare pose reproduction with and without 3D-RISM receptor desolvation. Pose reproduction docking with 3D-RISM yields a 1.8 +/- 2.41% increase in success rate compared to docking without 3D-RISM. Accounting for receptor desolvation provides a small, but significant, improvement in both enrichment and pose reproduction for this set. We tested the covalent attach-and-grow algorithm on 70 KRAS systems containing covalent ligands, obtaining similar pose reproduction success rates between covalent and noncovalent docking. Comparing covalent docking to noncovalent docking, there is a 2.4 +/- 3.29% increase and a 1.27 +/- 3.33% decline in the success rate when docking with experimental and SMILES-generated ligand conformations, respectively. As a proof-of-concept, we performed covalent virtual screens with and without receptor desolvation scoring, targeting the switch II pocket of KRAS, using 3.4 million make-on-demand acrylamide compounds from the Enamine REAL database. On average, the attach-and-grow algorithm spends approximately 17.61 s per molecule across the screen. The test set is available at https://github.com/tbalius/teb_docking_test_sets.


  • Open Access

    Development of receptor desolvation scoring and covalent sampling in DOCK 6: methods evaluated on a RAS test set

    by Y. Stanley Tan, Mayukh Chakrabarti, Reed M Stein, Lauren E Prentis, Robert C Rizzo, Tom Kurtzman, Marcus Fischer, Trent E Balius

    Molecular docking methods are widely used in drug discovery efforts. RAS proteins are important cancer drug targets, and are useful systems for evaluating docking methods, including accounting for solvation effects and covalent small molecule binding. Water often plays a key role in small molecule binding to RAS proteins, and many inhibitors, including approved drugs, covalently bind to oncogenic RAS proteins. We assembled a RAS test set, consisting of 138 RAS protein structures and 2 structures of KRAS DNA in complex with ligands. In DOCK 6, we have implemented a receptor desolvation scoring function and a covalent docking algorithm. These new features were evaluated using the test set, with pose reproduction, cross-docking, and enrichment calculations. We tested two solvation methods for generating receptor desolvation scoring grids: GIST, and 3D-RISM. Using grids from GIST or 3D-RISM, water displacements are precomputed with Gaussian-weighting, and trilinear interpolation is used to speed up this scoring calculation. To test receptor desolvation scoring, we prepared GIST and 3D-RISM grids for all KRAS systems in the test set, and we compare enrichment performance with and without receptor desolvation. Accounting for receptor desolvation using GIST improves enrichment for 51% of systems, while using 3D-RISM improves enrichment for 44% of systems. To more rigorously test accounting for receptor desolvation using 3D-RISM, we compare pose reproduction with and without 3D-RISM receptor desolvation. Pose reproduction docking with 3D-RISM yields a 5.5% increase in success rate compared to docking without 3D-RISM. Accounting for receptor desolvation provides a small, but significant, improvement in both enrichment and pose reproduction for this set. We tested the covalent attach-and-grow algorithm on 70 KRAS systems containing covalent ligands, obtaining similar pose reproduction success rates between covalent and noncovalent docking. Comparing covalent docking to noncovalent docking, there is a 7.2% increase and a 2.9% decline in success rate when docking with experimental and SMILES-generated ligand conformations, respectively. As a proof-of-concept, we performed covalent virtual screens with and without receptor desolvation scoring, targeting the switch II pocket of KRAS, using 3.4 million make-on-demand acrylamide compounds from the Enamine REAL database. On average, the attach-and-grow algorithm spends approximately 17.61 seconds per molecule across the screen. The test set is available at https://github.com/tbalius/teb_docking_test_sets.

  • Considerations Around Structure-Based Drug Discovery for KRAS Using DOCK

    by Mayukh Chakrabarti, Y. Stanley Tan, Trent E. Balius

    Molecular docking is a popular computational tool in drug discovery. Leveraging structural information, docking software predicts binding poses of small molecules to cavities on the surfaces of proteins. Virtual screening for ligand discovery is a useful application of docking software. In this chapter, using the enigmatic KRAS protein as an example system, we endeavor to teach the reader about best practices for performing molecular docking with UCSF DOCK. We discuss methods for virtual screening and docking molecules on KRAS. We present the following six points to optimize our docking setup for prosecuting a virtual screen: protein structure choice, pocket selection, optimization of the scoring function, modification of sampling spheres and sampling procedures, choosing an appropriate portion of chemical space to dock, and the choice of which top scoring molecules to pick for purchase. Key words Molecular docking DOCK Virtual screening Druggable pockets Computational drug discovery


  • Open Access

    Structural dynamics of RAF1-HSP90-CDC37 and HSP90 complexes reveal asymmetric client interactions and key structural elements

    by Lorenzo I. Finci, Mayukh Chakrabarti, Gulcin Gulten, Joseph Finney, Carissa Grose, Tara Fox, Renbin Yang, Dwight V. Nissley, Frank McCormick, Dominic Esposito, et al.

    RAF kinases are integral to the RAS-MAPK signaling pathway, and proper RAF1 folding relies on its interaction with the chaperone HSP90 and the cochaperone CDC37. Understanding the intricate molecular interactions governing RAF1 folding is crucial for comprehending this process. Here, we present a cryo-EM structure of the closed-state RAF1-HSP90-CDC37 complex, where the C-lobe of the RAF1 kinase domain binds to one side of the HSP90 dimer, and an unfolded N-lobe segment of the RAF1 kinase domain threads through the center of the HSP90 dimer. CDC37 binds to the kinase C-lobe, mimicking the N-lobe with its HxNI motif. We also describe structures of HSP90 dimers without RAF1 and CDC37, displaying only N-terminal and middle domains, which we term the semi-open state. Employing 1 μs atomistic simulations, energetic decomposition, and comparative structural analysis, we elucidate the dynamics and interactions within these complexes. Our quantitative analysis reveals that CDC37 bridges the HSP90-RAF1 interaction, RAF1 binds HSP90 asymmetrically, and that HSP90 structural elements engage RAF1’s unfolded region. Additionally, N- and C-terminal interactions stabilize HSP90 dimers, and molecular interactions in HSP90 dimers rearrange between the closed and semi-open states. Our findings provide valuable insight into the contributions of HSP90 and CDC37 in mediating client folding.


  • Open Access

    DOCK 6: Incorporating hierarchical traversal through precomputed ligand conformations to enable large‐scale docking

    by Trent E. Balius, Y. Stanley Tan, Mayukh Chakrabarti

    To allow DOCK 6 access to unprecedented chemical space for screening billions of small molecules, we have implemented features from DOCK 3.7 into DOCK 6, including a search routine that traverses precomputed ligand conformations stored in a hierarchical database. We tested them on the DUDE‐Z and SB2012 test sets. The hierarchical database search routine is 16 times faster than anchor‐and‐grow. However, the ability of hierarchical database search to reproduce the experimental pose is 16% worse than that of anchor‐and‐grow. The enrichment performance is on average similar, but DOCK 3.7 has better enrichment than DOCK 6, and DOCK 6 is on average 1.7 times slower. However, with post‐docking torsion minimization, DOCK 6 surpasses DOCK 3.7. A large‐scale virtual screen is performed with DOCK 6 on 23 million fragment molecules. We use current features in DOCK 6 to complement hierarchical database calculations, including torsion minimization, which is not available in DOCK 3.7.


  • Open Access

    DOCK 6: Incorporating hierarchical traversal through precomputed ligand conformations to enable large-scale docking

    by Trent E. Balius, Mayukh Chakrabarti, Y. Stanley Tan

    To allow DOCK 6 access to unprecedented chemical space for screening billions of small molecules, we have implemented features from DOCK 3.7 into DOCK 6, including a search routine that traverses precomputed ligand conformations stored in a hierarchical database. We tested them on the DUDE-Z and SB2012 test sets. The hierarchical database search routine is 16 times faster than anchor-and-grow. However, the ability of hierarchical database search to reproduce the experimental pose is 16% worse than that of anchor-and-grow. The enrichment performance is on average similar, but DOCK 3.7 has better enrichment than DOCK 6, and DOCK 6 is on average 1.7 times slower. However, with post-docking torsion minimization, DOCK 6 surpasses DOCK 3.7. A large-scale virtual screen is performed with DOCK 6 on 23 million fragment molecules. We use current features in DOCK 6 to complement hierarchical database calculations, including torsion minimization, which is not available in DOCK 3.7.


  • Publisher Correction: A practical guide to large-scale docking

    by Brian J. Bender, Stefan Gahbauer, Andreas Luttens, Jiankun Lyu, Chase M. Webb, Reed M. Stein, Elissa A. Fink, Trent E. Balius, Jens Carlsson, John J. Irwin, et al.